Canada - English - Health Canada

auro pharma inc - amoxicillin (amoxicillin trihydrate) - powder for suspension - 250mg - amoxicillin (amoxicillin trihydrate) 250mg - aminopenicillins

Canada - English - Health Canada

jamp pharma corporation - amoxicillin (amoxicillin trihydrate) - capsule - 250mg - amoxicillin (amoxicillin trihydrate) 250mg - aminopenicillins

Canada - English - Health Canada

jamp pharma corporation - amoxicillin (amoxicillin trihydrate) - capsule - 500mg - amoxicillin (amoxicillin trihydrate) 500mg - aminopenicillins

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to apx-amoxicillin/clavulanic acid 875/125 tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to apx-amoxicillin/clavulanic acid 875/125 tablets should not require the addition of another antibiotic due to the amoxycillin content of apx-amoxicillin/clavulanic acid 875/125 tablets. short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam/muric tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam/muric tablets should not require the addition of another antibiotic due to the amoxycillin content of curam/muric tablets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility apx-amoxicillin/clavulanic acid 500/125 tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to apx-amoxicillin/clavulanic acid 500/125 tablets should not require the addition of another antibiotic due to the amoxycillin content of apx-amoxicillin/clavulanic acid 500/125 tablets.

Canada - English - Health Canada

jamp pharma corporation - amoxicillin (amoxicillin trihydrate) - powder for suspension - 125mg - amoxicillin (amoxicillin trihydrate) 125mg

Canada - English - Health Canada

jamp pharma corporation - amoxicillin (amoxicillin trihydrate) - powder for suspension - 250mg - amoxicillin (amoxicillin trihydrate) 250mg

Canada - English - Health Canada

auro pharma inc - amoxicillin (amoxicillin trihydrate) - capsule - 250mg - amoxicillin (amoxicillin trihydrate) 250mg - aminopenicillins

Canada - English - Health Canada

auro pharma inc - amoxicillin (amoxicillin trihydrate) - capsule - 500mg - amoxicillin (amoxicillin trihydrate) 500mg - aminopenicillins

United States - English - NLM (National Library of Medicine)

sandoz inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only beta-lactamase–negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin is indicated in the treatment of infections due to susceptible (only beta-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . amoxicillin is indicated in the treatment of infections due to susceptible (only beta-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . amoxicillin is indicated in the treatment of infections due to susceptible (only beta-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, staphylococcus spp., or h. influenzae . amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with h. pylori inf